Rayan Mohamed‐Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rayan Mohamed‐Ahmed has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Dudley Robinson
Department of Urogynaecology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK
4 shared publications- Dudley Robinson
Department of Urogynaecology King's College Hospital London UK
4 shared publications Linda Cardozo
King's College Hospital NHS Foundation Trust Ringgold Standard Institution London UK
3 shared publications- Paul Abrams
Bristol Urological Institute, Southmead Hospital Bristol UK
3 shared publications A. Rantell
Kings Coll Hosp London, Dept Urogynaecol, Golden Jubilee Wing, London SE5 9RS, England
2 shared publicationsA. Taithongchai
Kings Coll Hosp London, Dept Urogynaecol, Golden Jubilee Wing, London SE5 9RS, England
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 325, 115321
Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis
- 21 July 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 325, 115321
Open AccessComparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis
- Open Access
- 19 May 2026
- Published by Springer Nature in International Urogynecology Journal
- Vol. 37 (10) , 3263-3267
Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict
Background: Refractory overactive bladder (OAB) lacks formal definition and is poorly understood. Its management requires patients to choose an invasive treatment, including intravesical botulinum toxin A (BOTOX®), sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS), which have varying rates of efficacy and side effects. These decisions can be complex for patients to make, especially within the time constraints of outpatient clinic appointments. A new patient decision aid (PDA) has been developed to support patients during this shared decision-making process. Aim: This study assesses decisional conflict scores and patient satisfaction in those who use a novel PDA for refractory OAB. Methods: Consecutive new patients with refractory OAB were provided with the PDA prior to decision-making. Patients then had a virtual follow-up appointment to assess their decisional conflict, using a validated scale. The total decisional conflict score was calculated. Treatment choice and free-text feedback were also analysed. Results: Twenty-five patients were included. Following use of the PDA, a range of treatment choices were made, including SNM ( n = 6), PTNS ( n = 10), BOTOX® ( n = 6) and continuation with medical therapy ( n = 3). Overall, decisional conflict was low, with 100% of patients having a score of less than 25. Subscores suggested improved patient understanding, with the PDA increasing clarification. Conclusion: Introduction of this novel PDA, in those requiring treatment for refractory OAB, was associated with low decisional conflict and positive patient feedback. This supports its use in shared decision-making, empowering patients to make an informed and individualised choice regarding their treatment.
- 19 May 2026
- Published by Springer Nature in International Urogynecology Journal
- Vol. 37 (10) , 3263-3267
Open AccessDecision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict
Background: Refractory overactive bladder (OAB) lacks formal definition and is poorly understood. Its management requires patients to choose an invasive treatment, including intravesical botulinum toxin A (BOTOX®), sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS), which have varying rates of efficacy and side effects. These decisions can be complex for patients to make, especially within the time constraints of outpatient clinic appointments. A new patient decision aid (PDA) has been developed to support patients during this shared decision-making process. Aim: This study assesses decisional conflict scores and patient satisfaction in those who use a novel PDA for refractory OAB. Methods: Consecutive new patients with refractory OAB were provided with the PDA prior to decision-making. Patients then had a virtual follow-up appointment to assess their decisional conflict, using a validated scale. The total decisional conflict score was calculated. Treatment choice and free-text feedback were also analysed. Results: Twenty-five patients were included. Following use of the PDA, a range of treatment choices were made, including SNM ( n = 6), PTNS ( n = 10), BOTOX® ( n = 6) and continuation with medical therapy ( n = 3). Overall, decisional conflict was low, with 100% of patients having a score of less than 25. Subscores suggested improved patient understanding, with the PDA increasing clarification. Conclusion: Introduction of this novel PDA, in those requiring treatment for refractory OAB, was associated with low decisional conflict and positive patient feedback. This supports its use in shared decision-making, empowering patients to make an informed and individualised choice regarding their treatment.
- Open Access
- 11 March 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (7) , 1398-1404
Current practice of colposuspension in the United Kingdom: Results of a national survey
Introduction: Colposuspension procedures have increased in the UK following the 2018 suspension of vaginal mesh for stress urinary incontinence. However, significant variation exists in preoperative assessment, patient selection, surgical approach, and postoperative care. This survey aims to explore current national practice. Material and Methods: A questionnaire was distributed to members of the British Society of Urogynaecology (BSUG) and the British Association of Urological Surgeons (BAUS). Results: Fifty‐three clinicians responded; most were gynecologists with a special interest in urogynecology (60%) or urogynecology subspecialists (34%). Response rates were 12% (51/442) among BSUG members and 20 for 2%. Most surgeons (85%) perform preoperative urodynamics in all patients, while 15% restrict testing to women with mixed symptoms. Almost all (98.1%) would treat detrusor overactivity or symptomatic overactive bladder prior to offering colposuspension. Forty‐five percent will perform colposuspension at any functional or maximum cytometric capacity; others use cutoffs of >400 mL (19%), >300 mL (26%) or >200 mL (10%). Fifty‐five percent reported a BMI limit of <35, while 19% have no limit. Most surgeons favored an open approach (58%), followed by laparoscopic (38%) and robotic (4%). Sutures were usually suspended tension‐free (75%) using Ethibond (53%) or PDS (40%), with 72% consenting for the use of non‐absorbable sutures. For open colposuspension, two sutures bilaterally were preferred (49%), followed by three (40%) and four (11%). Laparoscopic or robotic procedures were mostly intra‐peritoneal (89%), with surgeons placing two sutures bilaterally (88%) and tying their knots extracorporeally (75%). Thirty‐nine percent close the peritoneum over their sutures. Routine check cystoscopy was performed by 60%. Postoperatively, indwelling urinary catheters are mostly left on free drainage (69%); 17% always use a suprapubic catheter and 4% preferred clean intermittent self‐catheterization. Trial without catheter is most commonly attempted on Day 1 post‐colposuspension (74%), with variable voiding criteria and acceptable post‐void residuals. Conclusion: This national survey highlights marked heterogeneity in UK colposuspension practice. There is a need for comparative studies and national consensus on core technical steps to ensure safety and favorable long‐term outcomes.
- 11 March 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (7) , 1398-1404
Open AccessCurrent practice of colposuspension in the United Kingdom: Results of a national survey
Introduction: Colposuspension procedures have increased in the UK following the 2018 suspension of vaginal mesh for stress urinary incontinence. However, significant variation exists in preoperative assessment, patient selection, surgical approach, and postoperative care. This survey aims to explore current national practice. Material and Methods: A questionnaire was distributed to members of the British Society of Urogynaecology (BSUG) and the British Association of Urological Surgeons (BAUS). Results: Fifty‐three clinicians responded; most were gynecologists with a special interest in urogynecology (60%) or urogynecology subspecialists (34%). Response rates were 12% (51/442) among BSUG members and 20 for 2%. Most surgeons (85%) perform preoperative urodynamics in all patients, while 15% restrict testing to women with mixed symptoms. Almost all (98.1%) would treat detrusor overactivity or symptomatic overactive bladder prior to offering colposuspension. Forty‐five percent will perform colposuspension at any functional or maximum cytometric capacity; others use cutoffs of >400 mL (19%), >300 mL (26%) or >200 mL (10%). Fifty‐five percent reported a BMI limit of <35, while 19% have no limit. Most surgeons favored an open approach (58%), followed by laparoscopic (38%) and robotic (4%). Sutures were usually suspended tension‐free (75%) using Ethibond (53%) or PDS (40%), with 72% consenting for the use of non‐absorbable sutures. For open colposuspension, two sutures bilaterally were preferred (49%), followed by three (40%) and four (11%). Laparoscopic or robotic procedures were mostly intra‐peritoneal (89%), with surgeons placing two sutures bilaterally (88%) and tying their knots extracorporeally (75%). Thirty‐nine percent close the peritoneum over their sutures. Routine check cystoscopy was performed by 60%. Postoperatively, indwelling urinary catheters are mostly left on free drainage (69%); 17% always use a suprapubic catheter and 4% preferred clean intermittent self‐catheterization. Trial without catheter is most commonly attempted on Day 1 post‐colposuspension (74%), with variable voiding criteria and acceptable post‐void residuals. Conclusion: This national survey highlights marked heterogeneity in UK colposuspension practice. There is a need for comparative studies and national consensus on core technical steps to ensure safety and favorable long‐term outcomes.
- 26 November 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (5) , 1003-1010
Is There Evidence of Diagnostic and Treatment Gaps for LUTS in Post‐Menopausal Women With Genitourinary Syndrome of the Menopause? ICI‐RS 2025
Aims: This report, from the International Consultation on Incontinence‐Research Society, aims to evaluate the existing evidence and identify diagnostic and treatment gaps for Lower Urinary Tract Symptoms (LUTS) in post‐menopausal women with Genitourinary Syndrome of Menopause (GSM). Methods: An overview on the current literature, including pathophysiology, diagnosis and management of GSM associated LUTS, including incontinence, overactive bladder, underactive bladder and recurrent urinary tract infections (rUTIs). Results: Significant gaps in the literature were identified. GSM is underdiagnosed and the interplay between hormonal changes in the postmenopausal period on LUTS remains poorly understood. Diagnostic methods for rUTIs lack sensitivity and the role of the urinary microbiome is emerging. Current treatments, including topical oestrogens and systemic hormone therapy, lack long‐term efficacy data on LUTS. Evidence for regenerative medicine techniques remain limited by low‐quality studies and short‐term follow up. Conclusion: There is lack of high‐quality evidence, which hinders the optimal management of LUTS in post‐menopausal women with GSM. The panel proposes targeted research questions, focusing on the hormonal impact on the lower urinary tract, advancing diagnostics and robust clinical trials for existing and novel therapies, to bridge current gaps in the literature and improve patient care.
- 26 November 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (5) , 1003-1010
Is There Evidence of Diagnostic and Treatment Gaps for LUTS in Post‐Menopausal Women With Genitourinary Syndrome of the Menopause? ICI‐RS 2025
Aims: This report, from the International Consultation on Incontinence‐Research Society, aims to evaluate the existing evidence and identify diagnostic and treatment gaps for Lower Urinary Tract Symptoms (LUTS) in post‐menopausal women with Genitourinary Syndrome of Menopause (GSM). Methods: An overview on the current literature, including pathophysiology, diagnosis and management of GSM associated LUTS, including incontinence, overactive bladder, underactive bladder and recurrent urinary tract infections (rUTIs). Results: Significant gaps in the literature were identified. GSM is underdiagnosed and the interplay between hormonal changes in the postmenopausal period on LUTS remains poorly understood. Diagnostic methods for rUTIs lack sensitivity and the role of the urinary microbiome is emerging. Current treatments, including topical oestrogens and systemic hormone therapy, lack long‐term efficacy data on LUTS. Evidence for regenerative medicine techniques remain limited by low‐quality studies and short‐term follow up. Conclusion: There is lack of high‐quality evidence, which hinders the optimal management of LUTS in post‐menopausal women with GSM. The panel proposes targeted research questions, focusing on the hormonal impact on the lower urinary tract, advancing diagnostics and robust clinical trials for existing and novel therapies, to bridge current gaps in the literature and improve patient care.
- 23 April 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (9) , 1212-1219
Post‐Operative Pain After Pelvic Organ Prolapse Surgery (POPPOP): A Double Blind Randomised Multicentre Study to Assess the Effect of Local Anaesthesia During Vaginal Hysterectomy
Objective: To compare local anaesthetic with adrenaline (LAA) with normal saline for hydrodissection at vaginal hysterectomy.Design: A double‐blind, two parallel group multicentre randomised controlled trial (RCT) was planned.Setting: 217 women undergoing vaginal hysterectomy were screened in the five participating centres between March 2015 and December 2018.Population: 156 patients were recruited.Methods: Patients were randomised to Bupivacaine 0.25%/0.5% with adrenaline 1:200000 vesus normal saline. They completed baseline ‘pre‐operation’, ‘same day 3–6 h post‐op’ and ‘morning after surgery’ short‐form McGill pain questionnaire (SFMcGill).Main Outcome Measures: Primary endpoint was post‐operative pain measured using SFMcGill. Secondary endpoints included estimated blood loss (EBL), ease of dissection, severity of ooze, change in pre‐ and post‐operative haemoglobin, operating time, duration of inpatient stay and incidence of post‐operative morbidity.Results: There were no demographic differences between the groups. LAA was associated with significantly smaller increases in pain scores compared to placebo, both between pre‐operative and same‐day post‐operative (7.105 p < 0.001) and to the next day post‐operative (1.334 p < 0.001).Use of placebo infiltrate was associated with increased intra‐operative bleeding (difference in EBL 110 mL p < 0.001), increased severity of ooze (VAS difference 5.01 p < 0.001), and more difficult dissection (VAS difference 2.96 p < 0.001). There were no differences in pre‐operative or post‐operative measures of Hb, PCV, or post‐operative analgesia (p > 0.05). There were significantly more complications in the placebo arm (5 vs. 0, p = 0.02).Conclusions: This multicentre‐RCT demonstrated the value of LAA compared to normal saline as a paracervical infiltrate during vaginal hysterectomy under general anaesthesia: reduced intra‐operative blood loss, improved ease of dissection, decreased same and next day pain scores and complications.
- 23 April 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (9) , 1212-1219
Post‐Operative Pain After Pelvic Organ Prolapse Surgery (POPPOP): A Double Blind Randomised Multicentre Study to Assess the Effect of Local Anaesthesia During Vaginal Hysterectomy
Objective: To compare local anaesthetic with adrenaline (LAA) with normal saline for hydrodissection at vaginal hysterectomy.Design: A double‐blind, two parallel group multicentre randomised controlled trial (RCT) was planned.Setting: 217 women undergoing vaginal hysterectomy were screened in the five participating centres between March 2015 and December 2018.Population: 156 patients were recruited.Methods: Patients were randomised to Bupivacaine 0.25%/0.5% with adrenaline 1:200000 vesus normal saline. They completed baseline ‘pre‐operation’, ‘same day 3–6 h post‐op’ and ‘morning after surgery’ short‐form McGill pain questionnaire (SFMcGill).Main Outcome Measures: Primary endpoint was post‐operative pain measured using SFMcGill. Secondary endpoints included estimated blood loss (EBL), ease of dissection, severity of ooze, change in pre‐ and post‐operative haemoglobin, operating time, duration of inpatient stay and incidence of post‐operative morbidity.Results: There were no demographic differences between the groups. LAA was associated with significantly smaller increases in pain scores compared to placebo, both between pre‐operative and same‐day post‐operative (7.105 p < 0.001) and to the next day post‐operative (1.334 p < 0.001).Use of placebo infiltrate was associated with increased intra‐operative bleeding (difference in EBL 110 mL p < 0.001), increased severity of ooze (VAS difference 5.01 p < 0.001), and more difficult dissection (VAS difference 2.96 p < 0.001). There were no differences in pre‐operative or post‐operative measures of Hb, PCV, or post‐operative analgesia (p > 0.05). There were significantly more complications in the placebo arm (5 vs. 0, p = 0.02).Conclusions: This multicentre‐RCT demonstrated the value of LAA compared to normal saline as a paracervical infiltrate during vaginal hysterectomy under general anaesthesia: reduced intra‐operative blood loss, improved ease of dissection, decreased same and next day pain scores and complications.
- Open Access
- 16 January 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 661-667
Should We Be Treating Affective Symptoms, Like Anxiety and Depression Which May Be Related to LUTD in Patients With OAB? ICI‐RS 2024
Aims: To discuss the role of screening and treatment of affective symptoms, like anxiety and depression in patients with LUTD. A review of the literature regarding the bidirectional association and multidisciplinary approaches integrating psychometric assessments with personalized treatment plans to improve diagnostic accuracy and therapeutic outcomes of LUTD.Methods: This review summarizes discussions and a narrative review of (recent) literature during an International Consultation on Incontinence‐Research Society 2024 research proposal with respect to the role of screening for anxiety and depression, effect of mental health symptoms on treatment outcomes and future implications.Results: Consensus recognized the importance to incorporate attention to anxiety and depression in relation to LUTD. The awareness of this association can lead to better outcomes. Future research projects are proposed to evaluate the bidirectional relationship.Conclusion: The relationship between affective symptoms and LUTD underscores the need for integrated treatment approaches that address both psychological and urological dimensions. Further research is required to identify specific patient subgroups that would benefit most from these interventions, to develop standardized screening tools, and to refine treatment protocols. Multidisciplinary care, incorporating psychological assessment and personalized treatment strategies, could enhance outcomes for LUTD patients.
- 16 January 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 661-667
Open AccessShould We Be Treating Affective Symptoms, Like Anxiety and Depression Which May Be Related to LUTD in Patients With OAB? ICI‐RS 2024
Aims: To discuss the role of screening and treatment of affective symptoms, like anxiety and depression in patients with LUTD. A review of the literature regarding the bidirectional association and multidisciplinary approaches integrating psychometric assessments with personalized treatment plans to improve diagnostic accuracy and therapeutic outcomes of LUTD.Methods: This review summarizes discussions and a narrative review of (recent) literature during an International Consultation on Incontinence‐Research Society 2024 research proposal with respect to the role of screening for anxiety and depression, effect of mental health symptoms on treatment outcomes and future implications.Results: Consensus recognized the importance to incorporate attention to anxiety and depression in relation to LUTD. The awareness of this association can lead to better outcomes. Future research projects are proposed to evaluate the bidirectional relationship.Conclusion: The relationship between affective symptoms and LUTD underscores the need for integrated treatment approaches that address both psychological and urological dimensions. Further research is required to identify specific patient subgroups that would benefit most from these interventions, to develop standardized screening tools, and to refine treatment protocols. Multidisciplinary care, incorporating psychological assessment and personalized treatment strategies, could enhance outcomes for LUTD patients.
- Open Access
- 30 October 2024
- Published by Springer Nature in International Urogynecology Journal
- Vol. 36 (1) , 79-85
Patient Perception of Prolapse Condition Questionnaire: A Validated Patient-Reported Outcome Measure
Introduction and Hypothesis: Identifying patient-reported outcome measures allows management of urogenital prolapse to be tailored to reflect symptom bother and expectations of treatment. We devised a new single-item questionnaire, the Patient Perception of Prolapse Condition (PPPC), based on the Patient Perception of Bladder Condition (PPBC). The aim was to evaluate the criterion validity, test/re-test reliability and responsiveness of the PPPC. Methods: Women attending a tertiary urogynaecology clinic were recruited. At visit 1, patients completed the Prolapse Quality of Life (P-QOL) and PPPC questionnaires, and underwent a Pelvic Organ Prolapse Quantification (POP-Q) examination. This allowed assessment of criterion validity using Spearman’s rank correlation (rho) of the PPPC against validated subjective and objective outcomes. At visit 2, within the next 6 weeks, PPPC was repeated to assess test/re-test reliability using Cronbach's alpha (α). In those undergoing pelvic floor surgery, responsiveness of the PPPC was assessed at visit 3 by correlating PPPC and P-QOL scores 6 weeks post-operatively. Results: A total of 178 patients attended visit 1, 60 attended visit 2 and 58 attended visit 3. At visit 1, there were moderate correlations between the PPPC and both objective (POP-Q: rho = 0.385, p < 0.01, CI 0.192–0.549) and subjective (P-QOL: rho = 0.635, p < 0.01, CI 0.493–0.744) measures confirming criterion validity. Test/re-test reliability was high (α = 0.89). Correlation with post-operative PPPC and P-QOL confirmed moderate responsiveness (rho = 0.54, p < 0.01). Conclusion: The PPPC, a novel single-item patient-reported measure of prolapse condition, demonstrated good criterion validity, test/re-test reliability and responsiveness. These findings support the use of the PPPC as a global assessment of prolapse condition.
- 30 October 2024
- Published by Springer Nature in International Urogynecology Journal
- Vol. 36 (1) , 79-85
Open AccessPatient Perception of Prolapse Condition Questionnaire: A Validated Patient-Reported Outcome Measure
Introduction and Hypothesis: Identifying patient-reported outcome measures allows management of urogenital prolapse to be tailored to reflect symptom bother and expectations of treatment. We devised a new single-item questionnaire, the Patient Perception of Prolapse Condition (PPPC), based on the Patient Perception of Bladder Condition (PPBC). The aim was to evaluate the criterion validity, test/re-test reliability and responsiveness of the PPPC. Methods: Women attending a tertiary urogynaecology clinic were recruited. At visit 1, patients completed the Prolapse Quality of Life (P-QOL) and PPPC questionnaires, and underwent a Pelvic Organ Prolapse Quantification (POP-Q) examination. This allowed assessment of criterion validity using Spearman’s rank correlation (rho) of the PPPC against validated subjective and objective outcomes. At visit 2, within the next 6 weeks, PPPC was repeated to assess test/re-test reliability using Cronbach's alpha (α). In those undergoing pelvic floor surgery, responsiveness of the PPPC was assessed at visit 3 by correlating PPPC and P-QOL scores 6 weeks post-operatively. Results: A total of 178 patients attended visit 1, 60 attended visit 2 and 58 attended visit 3. At visit 1, there were moderate correlations between the PPPC and both objective (POP-Q: rho = 0.385, p < 0.01, CI 0.192–0.549) and subjective (P-QOL: rho = 0.635, p < 0.01, CI 0.493–0.744) measures confirming criterion validity. Test/re-test reliability was high (α = 0.89). Correlation with post-operative PPPC and P-QOL confirmed moderate responsiveness (rho = 0.54, p < 0.01). Conclusion: The PPPC, a novel single-item patient-reported measure of prolapse condition, demonstrated good criterion validity, test/re-test reliability and responsiveness. These findings support the use of the PPPC as a global assessment of prolapse condition.
- Open Access
- 27 July 2024
- Published by Elsevier in Continence
- Vol. 11
Long term safety, continuation rates and subjective and objective success of Posterior Tibial Nerve Stimulation for Overactive Bladder
- 27 July 2024
- Published by Elsevier in Continence
- Vol. 11
Open AccessLong term safety, continuation rates and subjective and objective success of Posterior Tibial Nerve Stimulation for Overactive Bladder
- 30 January 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 43 (6) , 1321-1327
Should hormone replacement therapy (any route of administration) be considered in all postmenopausal women with lower urinary tract symptoms? Report from the ICI‐RS 2023
Aims: This International Consultation on Incontinence‐Research Society report aims to summarize the evidence and uncertainties regarding the use of hormone replacement therapy by any route in the management of lower urinary tract symptoms (LUTS) including recurrent urinary tract infections (rUTI), with a review of special considerations for the elderly. Research question proposals to further this field have been highlighted.Methods: An overview of the existing evidence, guidelines, and consensus regarding the use of topical or systemic estrogens in the management of LUTS.Results: There are currently evidence and recommendations to offer topical estrogens to postmenopausal women with overactive bladder symptoms as well as postmenopausal women with rUTIs. Systemic estrogens however have been shown in a meta‐analysis to have a negative effect on LUTS and, therefore are not currently recommended.Conclusions: Although available evidence and recommendations exist for the use of topical estrogens, few women are commenced on these in primary care. There remain large gaps still within our knowledge of the use of estrogens within the management of LUTS, particularly on when it should be commenced, the length of time treatment should be continued for, and barriers to prescribing.
- 30 January 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 43 (6) , 1321-1327
Should hormone replacement therapy (any route of administration) be considered in all postmenopausal women with lower urinary tract symptoms? Report from the ICI‐RS 2023
Aims: This International Consultation on Incontinence‐Research Society report aims to summarize the evidence and uncertainties regarding the use of hormone replacement therapy by any route in the management of lower urinary tract symptoms (LUTS) including recurrent urinary tract infections (rUTI), with a review of special considerations for the elderly. Research question proposals to further this field have been highlighted.Methods: An overview of the existing evidence, guidelines, and consensus regarding the use of topical or systemic estrogens in the management of LUTS.Results: There are currently evidence and recommendations to offer topical estrogens to postmenopausal women with overactive bladder symptoms as well as postmenopausal women with rUTIs. Systemic estrogens however have been shown in a meta‐analysis to have a negative effect on LUTS and, therefore are not currently recommended.Conclusions: Although available evidence and recommendations exist for the use of topical estrogens, few women are commenced on these in primary care. There remain large gaps still within our knowledge of the use of estrogens within the management of LUTS, particularly on when it should be commenced, the length of time treatment should be continued for, and barriers to prescribing.
- Open Access
- 23 December 2023
- Published by Elsevier in Continence
- Vol. 9
Long term safety outcomes and continuation rates of repeated Intravesical Botulinum Toxin A injections for Detrusor Overactivity: 16 year’s experience of a Tertiary Centre in the UK
- 23 December 2023
- Published by Elsevier in Continence
- Vol. 9
Open AccessLong term safety outcomes and continuation rates of repeated Intravesical Botulinum Toxin A injections for Detrusor Overactivity: 16 year’s experience of a Tertiary Centre in the UK